TY - JOUR
T1 - Essential updates 2019/2020
T2 - Perioperative and surgical management of gastric cancer
AU - Irino, Tomoyuki
AU - Matsuda, Satoru
AU - Wada, Norihito
AU - Kawakubo, Hirofumi
AU - Kitagawa, Yuko
N1 - Publisher Copyright:
© 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery
PY - 2021/3
Y1 - 2021/3
N2 - Perioperative and surgical management of gastric cancer have been changing as pivotal phase II trials and landmark phase III trials offer new insights to the existing knowledge. The results of many landmark trials have been published or presented in the past year, many of which have changed or will change current clinical practice. For example, FLOT4 has completely changed the regimen of perioperative chemotherapy in Europe. Furthermore, evidence for minimally invasive surgery for clinical Stage I was firmly established by KLASS-01 and JCOG0912 for distal gastrectomy and CLASS-02, KLASS-03, and JCOG1401 for total gastrectomy. Moreover, promising results were provided by CLASS-01 and KLASS-02 for locally advanced gastric cancer. For adjuvant chemotherapy, JACCRO GC-07 (START-2) has provided a new doublet regimen for pathological Stage III, which is often refractory to chemotherapy. Conversely, JCOG0501 poses a significant challenge for advanced tumors, such as large type 3 and scirrhous (type 4) tumors. In this review, we briefly review recent updates and discuss future perspectives of gastric cancer treatment.
AB - Perioperative and surgical management of gastric cancer have been changing as pivotal phase II trials and landmark phase III trials offer new insights to the existing knowledge. The results of many landmark trials have been published or presented in the past year, many of which have changed or will change current clinical practice. For example, FLOT4 has completely changed the regimen of perioperative chemotherapy in Europe. Furthermore, evidence for minimally invasive surgery for clinical Stage I was firmly established by KLASS-01 and JCOG0912 for distal gastrectomy and CLASS-02, KLASS-03, and JCOG1401 for total gastrectomy. Moreover, promising results were provided by CLASS-01 and KLASS-02 for locally advanced gastric cancer. For adjuvant chemotherapy, JACCRO GC-07 (START-2) has provided a new doublet regimen for pathological Stage III, which is often refractory to chemotherapy. Conversely, JCOG0501 poses a significant challenge for advanced tumors, such as large type 3 and scirrhous (type 4) tumors. In this review, we briefly review recent updates and discuss future perspectives of gastric cancer treatment.
KW - adjuvant treatment
KW - cancer of the gastroesophageal junction
KW - gastric cancer
KW - minimally invasive surgery
KW - neoadjuvant treatment
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85100596196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100596196&partnerID=8YFLogxK
U2 - 10.1002/ags3.12438
DO - 10.1002/ags3.12438
M3 - Review article
AN - SCOPUS:85100596196
SN - 2475-0328
VL - 5
SP - 162
EP - 172
JO - Annals of Gastroenterological Surgery
JF - Annals of Gastroenterological Surgery
IS - 2
ER -
